The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
about
The impact of GPCR structures on pharmacology and structure-based drug designXimelagatran: direct thrombin inhibitorNew anticoagulants for the prevention and treatment of venous thromboembolismStructural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapyAdvances in the development of thrombin inhibitorsNovel therapies for the prevention of strokeBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondTreatment of heparin-induced thrombocytopenia.Direct thrombin inhibitors: pharmacology and clinical relevance.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Beyond heparin and warfarin: the new generation of anticoagulants.Thrombin inhibitors identified by computer-assisted multiparameter design.Ximelagatran (Exanta): alternative to warfarin?A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.The fourth mammalian molybdenum enzyme mARC: current state of research.Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines.The METHRO trials.Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study.Oral direct thrombin inhibitors in clinical development.Direct thrombin inhibitors for anticoagulation.Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.Stroke Prevention in Atrial Fibrillation: Where are We Now?Anticoagulant drugs: an update.The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation.Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondriaXimelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinXimelagatran for stroke prevention in atrial fibrillation.The status of new anticoagulants.Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.Influence of aromatic and aliphatic moieties on thrombin inhibitors potency.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
P2860
Q24628661-0000C34D-7B10-4822-804B-717E2EE89EFDQ24681333-ECBE326B-6B2B-46A4-BBE7-64E47260D492Q24681351-C01D8FFA-66DA-480D-B72A-151F89C1C72FQ27674646-B88B68C2-2FB3-4BC7-BD72-2801FFCB3885Q28182480-CADFF473-870B-42D0-87E3-23F22351ABD5Q28210724-0AA3010D-C73E-4E05-ACA7-22165332E472Q29994527-2632E37E-E385-4B29-AEB4-8A9B38A0AA70Q31042575-858E1102-7BAE-4F87-A0DD-D857E41B395BQ33366516-A1A724F4-5A52-406A-9647-6CB945D64F54Q33372266-1D7C080B-48AB-4B40-9D0B-46D4054303D9Q33374258-31D865F9-A9BD-4EBB-821D-BD9C3771B549Q33853948-7077A607-34B9-4A51-AD57-06BFEF3008F0Q33945088-67E8EDE2-EC38-4E40-8C62-D568D4523DF6Q33967251-A5E510CA-65A8-44B4-84DA-18E55D60F901Q34028677-A6F32CD0-5E70-463D-BA17-A3579B29A7F9Q34819094-6C61A8EC-8FA6-43A2-B25D-24E099538808Q35117100-F9AE7B8A-D313-4592-B803-B49B8663988FQ35144015-809DA2F8-4792-4AEF-BD47-75EF1593B1DBQ35219373-6C95FEB1-20A1-4E85-929A-AAECA05CFAFFQ35638059-2F70AF5A-8586-4FEB-869B-F76BB53AA6E6Q35777336-EDDBA37E-8BB3-407F-80DC-855C964E8B94Q35779232-FBEFEEF9-0760-41D0-BEEC-A8D608A5A1F2Q35811581-20B75DEB-65E9-43A6-B9A6-290343AC78A3Q35821887-8A658971-CA2B-4B0D-BB04-954E7A00CA49Q35827933-CD11D29E-D8AA-446E-8617-32F5E8992D08Q35838829-1420C480-DC82-4478-8429-2415509D8370Q35892171-1C91E617-54D0-479E-ACFE-F9A685104669Q35895188-B315123E-3F1D-4001-B16B-9647900D024CQ35996015-DF6D2243-22BB-45FE-BF61-4B0B41B2D51EQ36042279-73B489E8-BFB9-42EC-8711-E8BD97AFA04CQ36216784-3A99CE89-9DF8-47E7-847F-C53E107CF555Q36520745-DD09231A-8D5A-4E19-8DAE-7805F2DD7900Q36884659-13513E39-5DDD-42C3-91A7-BD9EEEC18896Q37063928-C648E943-6D40-47CF-BF57-409587A14C14Q37428883-6209F6BF-5B6B-41FC-9188-F0A557DC8178Q37871535-92C4338C-F57F-448C-918C-BE9AE8CDFC03Q42141062-2426AA3D-5453-4E07-BE6E-D36B5B37B66EQ44438922-CCBB7A28-6569-43D9-A8DF-BC585BCCC112Q44518804-D5628A2F-CC58-41F2-B743-EEC2FED543FAQ44518890-99F9AADC-E4B2-4F69-AB61-54769CB6D9EE
P2860
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@ast
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@en
type
label
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@ast
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@en
prefLabel
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@ast
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@en
P2093
P1433
P1476
The direct thrombin inhibitor ...... l and pharmacodynamic effects.
@en
P2093
A Abrahamsson
D Gustafsson
E Gyzander
H Sörensen
K Hoffmann
S Carlsson
P304
P356
10.1016/S0049-3848(00)00399-6
P577
2001-02-01T00:00:00Z